|
Market Closed -
NSE India S.E.
07:05:07 2026-10-29 EDT
|
5-day change | 1st Jan Change | ||
| 3,459.70 INR | -0.00% |
|
+6.12% | +24.95% |
| 10-09 | Ajanta Pharma Usa Inc Announces Recall of Ranolazine Extended-Release Tablets 1000 Mg | CI |
| 09-23 | Ajanta Pharma's Geographical Diversification Delivers |  |
| Market Cap | 432B 4.54B 4.07B 3.75B 3.39B 6.35B 6.45B 44.75B 17.85B 226B 17.03B 16.67B 716B | P/E 2027 * |
34.5x | P/E 2028 * | 29.6x |
|---|---|---|---|---|---|
| Enterprise Value | 423B 4.45B 3.98B 3.67B 3.32B 6.22B 6.32B 43.82B 17.48B 222B 16.68B 16.33B 702B | EV / Sales 2027 * |
6.73x | EV / Sales 2028 * | 5.9x |
| Free-Float |
36.42% | Yield 2027 * |
1.01% | Yield 2028 * | 1.17% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| AJANTPHARM | Delayed | |
Bombay S.E.
| AJANTPHARM | Delayed |
Last Transcript: Ajanta Pharma Limited
| 1 week | +6.12% | ||
| Current month | -4.45% | ||
| 1 month | -1.86% | ||
| 3 months | +3.51% | ||
| 6 months | +25.53% | ||
| Current year | +24.95% |
| 1 week | 3,224.3 |  | 3,529.3 |
| 1 month | 3,199.9 | | 3,758.9 |
| Current year | 2,654.5 | | 3,796 |
| 1 year | 2,430 | | 3,796 |
| 3 years | 1,730.9 | | 3,796 |
| 5 years | 1,061.77 | | 3,796 |
| 10 years | 550 | | 3,796 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | - | |
| Chief Executive Officer | 54 | 2009-12-20 | |
| Director of Finance/CFO | 61 | 1998-04-22 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 1995-12-31 | |
| Chairman | 79 | 1979-12-30 | |
| Director/Board Member | 71 | 2009-12-20 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 2/28/25 | Sell | 548 | 0.0004% | |||
| 12/31/24 | Sell | 100 | 0.0001% | |||
| 12/31/24 | Sell | 51 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.00% | +6.12% | +44.85% | +97.03% | 4.54B | |
| +6.63% | +5.13% | +68.86% | +145.20% | 1,148B | |
| +1.53% | +2.84% | +47.48% | +89.01% | 652B | |
| +1.68% | +1.96% | +29.16% | +109.31% | 505B | |
| +0.73% | +2.47% | +53.85% | +68.96% | 384B | |
| +3.83% | -0.62% | +69.01% | +42.32% | 348B | |
| +2.38% | +4.27% | +33.81% | +57.95% | 294B | |
| +2.26% | +3.47% | +5.21% | +28.92% | 264B | |
| +1.97% | +3.01% | +57.91% | +76.14% | 244B | |
| +4.03% | +5.36% | +39.76% | +116.14% | 197B | |
| Average | +2.11% | +1.86% | +44.99% | +83.10% | 404.17B | |
| Weighted average by Cap. | +2.25% | +1.51% | +50.22% | +95.97% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 62.93B 661M 592M 546M 494M 924M 939M 6.52B 2.6B 32.94B 2.48B 2.43B 104B | 70.97B 745M 667M 616M 557M 1.04B 1.06B 7.35B 2.93B 37.14B 2.8B 2.74B 118B |
| Net income | 12.52B 131M 118M 109M 98.32M 184M 187M 1.3B 517M 6.55B 493M 483M 20.75B | 14.62B 154M 138M 127M 115M 215M 218M 1.51B 604M 7.65B 576M 564M 24.24B |
| Net Debt | -8.95B -93.96M -84.16M -77.65M -70.26M -131M -134M -926M -370M -4.68B -353M -345M -14.83B | -13.7B -144M -129M -119M -108M -201M -204M -1.42B -566M -7.17B -540M -528M -22.7B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-29 | ₹3,459.70 | -0.00% | 43,183 |
| 26-10-28 | ₹3,459.80 | +3.17% | 43,733 |
| 26-10-27 | ₹3,353.60 | -0.81% | 174,374 |
| 26-10-26 | ₹3,381.00 | +2.96% | 107,072 |
| 26-10-23 | ₹3,283.90 | +0.41% | 154,847 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AJANTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
